Literature DB >> 12430869

Stem cell transplantation for thalassemia.

Surapol Issaragrisil1.   

Abstract

Thalassemia, one of the most common genetic disorders, is considered to be a global problem. Several millions of the patients suffer from severe thalassemic diseases. Stem cell transplantation is currently the only curative therapy. Bone marrow transplantation offers a high probability of cure when performed in young children. There is a higher risk as the patient becomes older, especially the high incidence of graft rejection. Modified conditioning regimens live been developed to overcome graft rejection in patients with class III or full blown manifestations. The alternative use of stem cell from cord blood makes possible earlier transplant with better chance of cure, although the engraftment is slower compared to bone marrow transplantation. More experiences with regard to stem cell transplantation in adult patients, the use of stem cell transplantation from related donors as well as matched unrelated donors are necessary.

Entities:  

Mesh:

Year:  2002        PMID: 12430869     DOI: 10.1007/bf03165269

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  The distribution of the thalassemia gene: a historical review.

Authors:  A I CHERNOFF
Journal:  Blood       Date:  1959-08       Impact factor: 22.113

2.  Brief report: transplantation of cord-blood stem cells into a patient with severe thalassemia.

Authors:  S Issaragrisil; S Visuthisakchai; V Suvatte; V S Tanphaichitr; D Chandanayingyong; T Schreiner; S Kanokpongsakdi; N Siritanaratkul; A Piankijagum
Journal:  N Engl J Med       Date:  1995-02-09       Impact factor: 91.245

3.  Growth in children after bone marrow transplantation for thalassemia.

Authors:  J Gaziev; M Galimberti; C Giardini; D Baronciani; G Lucarelli
Journal:  Bone Marrow Transplant       Date:  1993       Impact factor: 5.483

4.  Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.

Authors:  M Aker; J Kapelushnik; T Pugatsch; E Naparstek; S Ben-Neria; O Yehuda; A Amar; A Nagler; S Slavin; R Or
Journal:  J Pediatr Hematol Oncol       Date:  1998 Mar-Apr       Impact factor: 1.289

Review 5.  Clinical and hematologic aspects of hemoglobin E beta-thalassemia.

Authors:  S Fucharoen; P Winichagoon
Journal:  Curr Opin Hematol       Date:  2000-03       Impact factor: 3.284

6.  Marrow transplantation for patients with thalassemia: results in class 3 patients.

Authors:  G Lucarelli; R A Clift; M Galimberti; P Polchi; E Angelucci; D Baronciani; C Giardini; M Andreani; M Manna; S Nesci; F Agostinelli; S Rapa; M Ripalti; F Albertini
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

7.  Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia.

Authors:  C Giardini; M Galimberti; G Lucarelli; P Polchi; E Angelucci; D Baronciani; D Gaziev; B Erer; G La Nasa; I Barbanti
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

8.  Growth and endocrine function following bone marrow transplantation for thalassemia.

Authors:  M De Simone; P Olioso; P Di Bartolomeo; G Di Girolamo; G Farello; M Palumbo; G Papalinetti; P Bavaro; F Angrilli; G Torlontano
Journal:  Bone Marrow Transplant       Date:  1995-02       Impact factor: 5.483

9.  Thalassemia in the next millennium. Keynote address.

Authors:  D J Weatherall
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

10.  Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.

Authors:  D Gaziev; M Galimberti; G Lucarelli; P Polchi; C Giardini; E Angelucci; D Baronciani; P Sodani; B Erer; M D Biagi; M Andreani; F Agostinelli; M Donati; S Nesci; N Talevi
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

View more
  3 in total

1.  Development of a fibrous DNA chip for cost-effective β-thalassemia genotyping.

Authors:  Wakako Suzuki; Takashi Osaka; Akihiko Sekizawa; Michihiro Kitagawa; Ikuo Honma
Journal:  Int J Hematol       Date:  2012-07-31       Impact factor: 2.490

2.  Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China.

Authors:  Xin-Yu Li; Xin Sun; Jing Chen; Mao-Quan Qin; Zuo Luan; Yi-Ping Zhu; Jian-Pei Fang
Journal:  World J Pediatr       Date:  2018-03-06       Impact factor: 2.764

3.  Invasive molecular prenatal diagnosis of alpha and beta thalassemia among Hakka pregnant women.

Authors:  Heming Wu; Huaxian Wang; Liubing Lan; Mei Zeng; Wei Guo; Zhiyuan Zheng; Huichao Zhu; Jie Wu; Pingsen Zhao
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.